ADHD Research in the Last 5 Years — The Most Important Findings (2020–2025)
Biomarker studies, neuroimaging advances, epigenetic data, and DSM debates — the most significant turning points in ADHD science between 2020 and 2025.
Neurobiology — Brain Networks and Structural Differences
Over the last five years, advances in neuroimaging technology and large-scale data consortia have allowed us to visualize the ADHD brain with increasing resolution each year.
ENIGMA Consortium meta-analysis: This meta-analysis covering more than 4,000 participants across different countries found that ADHD individuals show significantly smaller volumes in the cerebellum, striatum, and nucleus accumbens compared to controls. This finding concretizes the evidence that ADHD is not "just an attention problem" but a neurodevelopmental difference encompassing motor coordination and reward processing systems.
DMN-TPN switching dysfunction: The Default Mode Network is a network that is active at rest and should deactivate during tasks. In ADHD, fMRI studies have reconfirmed that this network fails to fully deactivate during tasks — and its coordination with the Task Positive Network is disrupted. This finding provides a neurobiological answer to "why can't I focus?"
Brain maturation delay: Shaw et al.'s 2007 model proposing that the prefrontal cortex matures 3–5 years later in ADHD was strongly reinforced by longitudinal studies conducted between 2020 and 2025.
---
Genetics and Epigenetics — Mapping the Biological Inheritance
Genome-Wide Association Studies (GWAS): Large GWAS studies in 2019 and 2022 identified more than 200 genetic variants associated with ADHD. There is no single "ADHD gene"; instead, the cumulative effect of numerous variants, each with small effect sizes, is at work.
Polygenic risk scores: These findings open the door to a world where clinicians can statistically measure a person's probability of developing ADHD through DNA analysis. Not yet standard in clinical practice, but actively used in research settings.
Transgenerational epigenetics: Animal studies and some human data show that epigenetic changes caused by stress and environmental toxins can be transmitted across multiple generations. This provides a biological foundation for the hypothesis that "what my parents experienced may leave traces in my brain."
---
Diagnosis and Classification — DSM Debates
The heterogeneity problem: The symptoms, cognitive profiles, and treatment responses of people diagnosed with ADHD are extremely varied. This reality has moved the question "is there one ADHD?" to the center of the academic agenda. Some researchers propose that ADHD is not a single disorder but an "umbrella category" sharing common symptoms.
Biotype research: While Dr. Daniel Amen's proposed 7 ADHD biotype model remains contested, neuroimaging-based classification approaches are gaining momentum. Between 2020–2025, biotype research settled onto more systematic footing.
ICD-11 update (2022): The World Health Organization's new classification system refined ADHD diagnostic criteria, created more space for adult presentations, and brought the attention component into greater prominence.
---
Treatment and Pharmacology — New Approaches
Viloxazine (Qelbree): This new-generation non-stimulant, FDA approved in 2021, combines norepinephrine reuptake inhibition with serotonin modulation. Not yet available in Turkey, but the option palette may expand in the near term.
Pharmacogenomics: DNA analysis-based medication selection — predicting which genetic makeup responds better to which medication — is transitioning from research settings to clinical pilot applications. This can be seen as the beginning of the end of the "trial and error" era.
Digital therapeutics: EndeavorRx became the first FDA-approved ADHD digital game therapy (2020). It's positioned as a supplementary tool for executive function training in childhood ADHD.
Psychedelics and ADHD: First-phase studies examining the effects of psilocybin and MDMA on ADHD symptoms have begun. Results are still early and inconclusive, but this field is worth watching.